Despite Not Finishing University, This Man Gains 1,000% Profit in Biotechnology Stocks
Success is not always reserved for those with high levels of education. Bob Duggan, a successful entrepreneur, has achieved significant gains through investments in biotechnology stocks. His recent investment in Summit Therapeutics (SMMT) has surged by more than 1,000%.
According to The Wall Street Journal, the surge in the biopharmaceutical company’s shares occurred due to data from late-stage clinical trials showing that its drug, Ivonescentimab, outperformed Merck’s blockbuster cancer drug, Keytruda, in patients with lung cancer.
Duggan, who was already a billionaire before his investment in Summit, is now estimated to have a net worth of approximately US$16 billion. Nevertheless, several challenges remain regarding this drug, including its performance in global trials outside of China, where Summit licensed Ivonescimab from the Chinese biotech firm Akeso in 2022.
This is not the first time Duggan has achieved success in the biotechnology sector. Two decades ago, he invested in Pharmacyclics, a company that developed the cancer drug Imbruvica. After navigating various challenges, Pharmacyclics was eventually acquired by AbbVie for US$21 billion, establishing Duggan as a significant figure in the industry.
Duggan, now 80 years old, has proven that success in this industry is not exclusive to those with high academic backgrounds. Nathan Vardi, author of ‘For Blood and Money’, notes that while many argue Duggan is merely lucky, his ability to determine when to hold or exit an investment is the true key to his success.
Duggan’s experience across various industries, ranging from bakeries to robotics, provides him with a unique perspective when facing challenges. He believes that the outsider’s lack of conventional understanding, combined with the intensity he brings, allows him to take unconventional steps.
Ivonescimab, for instance, does not only function as a PD-1 protein binder to trigger the immune system but also inhibits the VEGF protein that supports tumour blood vessel growth. This dual mode of action is expected to provide a more potent effect in fighting cancer.
However, experts warn that this dual action could lead to safety issues in the future. Given the side effects observed in drugs targeting VEGF, analysts are awaiting further data to ensure the drug is safe and can improve patient survival rates.
While Summit has the opportunity to compete in the US$50 billion PD-1 market, the challenges in execution remain significant. Analysts warn that success will depend heavily on proper management and effective trial design strategies.
As the market processes the scale of the challenges facing Summit, the company’s shares are expected to remain volatile and could experience a decline following the price surge post-data release. With all eyes on Ivonescimab, the future of Duggan and Summit will remain a focal point for investors and analysts worldwide.